Sugammadex on Remifentanil Ce for Preventing Emergence Cough
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03583021|
Recruitment Status : Recruiting
First Posted : July 11, 2018
Last Update Posted : July 12, 2018
|Condition or disease||Intervention/treatment||Phase|
|Gallbladder Diseases||Drug: Sugammadex Injectable Product Drug: Neostigmine Injectable Product||Not Applicable|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||50 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Double (Participant, Care Provider)|
|Official Title:||Department of Anesthesiology and Pain Medicine, Ajou University School of Medicine|
|Actual Study Start Date :||June 25, 2018|
|Estimated Primary Completion Date :||December 31, 2019|
|Estimated Study Completion Date :||December 31, 2019|
Experimental: sugammadex group
Sugammadex group receives the intravenous sugammadex of 3 mg/kg.
Drug: Sugammadex Injectable Product
Sugammadex of 3 mg/kg is injected.
Placebo Comparator: neostigmine group
Neostigmine group receives the intravenous neostigmine 50 ug/kg and glycopyrrolate 10 ug/kg.
Drug: Neostigmine Injectable Product
Neostigmine of 50 ug/kg and Glycopyrrolate of 10 ug/kg are injected.
- optimal Ce of remifentanil [ Time Frame: from the ene of surgery until endotracheal extubation ]Using Dixon methods, evaluating of optimal Ce of remifentanil for preventing emergence cough following extubation during general anesthesia
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03583021
|Contact: Ji Eun Kimemail@example.com|
|Korea, Republic of|
|Department of Anesthesiology and Pain Medicine, Ajou University School of Medicine||Recruiting|
|Suwon, Seoul, Korea, Republic of|
|Contact: Ji Eun Kim 82-31-219-5575|
|Principal Investigator:||Ji Eun Kim||Ajou University School of Medicine|